MorphoSys AG (MOR) News
Filter MOR News Items
MOR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MOR News Highlights
- MOR's 30 day story count now stands at 2.
- Over the past 7 days, the trend for MOR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about MOR are AG and ASH.
Latest MOR News From Around the Web
Below are the latest news stories about MORPHOSYS AG that investors may wish to consider to help them evaluate MOR as an investment opportunity.
Optimistic Investors Push MorphoSys AG (ETR:MOR) Shares Up 48% But Growth Is LackingMorphoSys AG ( ETR:MOR ) shareholders would be excited to see that the share price has had a great month, posting a 48... |
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 StudyPLANEGG/MUNICH, Germany, December 11, 2023--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis. These findings were presented in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. |
Further weakness as MorphoSys (ETR:MOR) drops 39% this week, taking five-year losses to 84%Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish... |
MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis StudyThough data from the late study shows that treatment with MorphoSys' (MOR) combination therapy met its primary goal, it did not meet a secondary endpoint. |
FSR Stock Alert: Fisker Receives Non-Compliance Notice From NYSEFisker stock is falling on Tuesday as FSR investors react to a non-compliance notice and the resignation of its new CAO. |
Origin Materials Layoffs 2023: What to Know About the Latest ORGN Job CutsOrigin Materials layoffs have the company cutting 30% of its workforce as it plans to switch focus with a major restructuring. |
Why Is MorphoSys (MOR) Stock Down 20% Today?MorphoSys stock is falling on Tuesday with heavy trading of MOR shares despite the company posting positive data from a Phase 3 study. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! |
Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom ReductionPublication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%)The key secondary endpoints assessing symptom reduction, TSS50 ... |
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom ReductionPLANEGG/MUNICH, Germany, November 20, 2023--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced strong topline results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib compared with placebo plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis. |